Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Lymphoma, Diffuse Large-Cell: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Lymphoma, Diffuse Large-Cell: 1 US clinical trial tracked, none currently recruiting.

Lymphoma, Diffuse Large-Cell is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition lymphoma-diffuse-large-cell

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Lymphoma, Diffuse Large- (th…0%
Open-enrollment share among volume-matched conditions near Lymphoma, Diffuse Large-Cell

Lymphoma, Diffuse Large-Cell has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphoma, Diffuse Large-Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphoma, Diffuse Large-Cell is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Lymphoma, Diffuse Large-Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bendamustine Drug
1 trials
Rituximab Drug
1 trials

US sites by state

Facility locations filed on Lymphoma, Diffuse Large-Cell trials. A trial with sites in several states counts in each.

North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphoma, Diffuse Large-Cell page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, Diffuse Large-Cell condition card totals 1 registered trials; most-linked intervention Bendamustine; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.